| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3187116 | Annales de Dermatologie et de Vénéréologie | 2013 | 4 Pages |
Abstract
To our knowledge, this is the first clinical report of orbital myositis as an adverse event related to anti-CTLA-4 antibody treatment. Both timing and usual profile of adverse events support the hypothesis that orbital myositis has to be attributed there to ipilimumab. Several dysimmune toxicities were observed with ipilimumab. Ophtalmic toxicity has unusually been described. Most cases were uveitis. Whether immune-related adverse events correlate with clinical response to ipilimumab treatment remains to be determined.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
M. Lecouflet, M. Verschoore, C. Giard, P. Gohier, Y. Le Corre, D. Milea, L. Martin,